Electrocardiographic characteristics and metabolic risk factors associated with inappropriately high left ventricular mass in patients with electrocardiographic left ventricular hypertrophy: the LIFE Study.

Association of leukocyte telomere length with echocardiographic left ventricular mass: the Framingham heart study. Circulation (2009) 1.04

Genetic variants predicting left ventricular hypertrophy in a diabetic population: a Go-DARTS study including meta-analysis. Cardiovasc Diabetol (2013) 0.78

Electrocardiographic left ventricular hypertrophy with strain pattern: prevalence, mechanisms and prognostic implications. Cardiovasc J Afr (2008) 0.76

Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr (2005) 46.32

Heart disease and stroke statistics--2011 update: a report from the American Heart Association. Circulation (2010) 30.07

Biological, clinical and population relevance of 95 loci for blood lipids. Nature (2010) 28.21

Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet (2002) 23.18

Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index. Nat Genet (2010) 23.08

Hundreds of variants clustered in genomic loci and biological pathways affect human height. Nature (2010) 20.01

Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet (2003) 17.34

Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet (2012) 12.10

Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med (2008) 11.61

Recommendations for chamber quantification. Eur J Echocardiogr (2006) 11.39

Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med (2008) 10.03

Third universal definition of myocardial infarction. J Am Coll Cardiol (2012) 8.59

Third universal definition of myocardial infarction. Circulation (2012) 8.47

Third universal definition of myocardial infarction. Eur Heart J (2012) 7.98

Meta-analysis identifies 13 new loci associated with waist-hip ratio and reveals sexual dimorphism in the genetic basis of fat distribution. Nat Genet (2010) 7.94

Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med (2003) 7.86

Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J (2005) 7.75

Large-scale association analysis identifies new risk loci for coronary artery disease. Nat Genet (2012) 7.59

Telmisartan to prevent recurrent stroke and cardiovascular events. N Engl J Med (2008) 7.25

The revised Ghent nosology for the Marfan syndrome. J Med Genet (2010) 6.87

Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet (2002) 6.87

A genome-wide meta-analysis identifies 22 loci associated with eight hematological parameters in the HaemGen consortium. Nat Genet (2009) 6.31

Usual versus tight control of systolic blood pressure in non-diabetic patients with hypertension (Cardio-Sis): an open-label randomised trial. Lancet (2009) 6.25

Relationship of high and low ankle brachial index to all-cause and cardiovascular disease mortality: the Strong Heart Study. Circulation (2004) 6.15

Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. N Engl J Med (2008) 6.08

A multilocus genetic risk score for coronary heart disease: case-control and prospective cohort analyses. Lancet (2010) 6.07

Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension (2007) 5.61

Retracted Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): a randomised, open-label, blinded endpoint morbidity-mortality study. Lancet (2007) 5.17

Prognostic value of multidetector coronary computed tomographic angiography for prediction of all-cause mortality. J Am Coll Cardiol (2007) 4.49

Central pressure more strongly relates to vascular disease and outcome than does brachial pressure: the Strong Heart Study. Hypertension (2007) 4.20

Prognostic significance of left ventricular mass change during treatment of hypertension. JAMA (2004) 3.88

Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study. Ann Intern Med (2003) 3.78

Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy. JAMA (2002) 3.70

Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events. JAMA (2004) 3.68

Outcome of patients with low-gradient "severe" aortic stenosis and preserved ejection fraction. Circulation (2011) 3.38

State of the art: using natriuretic peptide levels in clinical practice. Eur J Heart Fail (2008) 3.35

Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol (2005) 3.27

Genome-wide meta-analysis identifies 11 new loci for anthropometric traits and provides insights into genetic architecture. Nat Genet (2013) 3.25

Novel loci for adiponectin levels and their influence on type 2 diabetes and metabolic traits: a multi-ethnic meta-analysis of 45,891 individuals. PLoS Genet (2012) 3.21

Effect of lower targets for blood pressure and LDL cholesterol on atherosclerosis in diabetes: the SANDS randomized trial. JAMA (2008) 3.16

Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial. Lancet (2010) 3.16

The impact of serum uric acid on cardiovascular outcomes in the LIFE study. Kidney Int (2004) 2.96

Coronary heart disease risk equivalence in diabetes depends on concomitant risk factors. Diabetes Care (2006) 2.90

Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial. JAMA (2007) 2.90

Retracted Effects of valsartan on morbidity and mortality in uncontrolled hypertensive patients with high cardiovascular risks: KYOTO HEART Study. Eur Heart J (2009) 2.83

Risk stratification with the risk chart from the European Society of Hypertension compared with SCORE in the general population. J Hypertens (2009) 2.71

Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: losartan intervention for endpoint reduction in hypertension study. Hypertension (2005) 2.69

Clinical practice. Patent foramen ovale in young adults with unexplained stroke. N Engl J Med (2005) 2.68

Preclinical carotid atherosclerosis in patients with rheumatoid arthritis. Ann Intern Med (2006) 2.68

The Anglo-Scandinavian Cardiac Outcomes Trial lipid lowering arm: extended observations 2 years after trial closure. Eur Heart J (2008) 2.65

Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial--lipid-lowering arm (ASCOT-LLA). Diabetes Care (2005) 2.59

Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial. Circulation (2004) 2.56

Cadmium exposure and incident cardiovascular disease. Epidemiology (2013) 2.55

Central but not brachial blood pressure predicts cardiovascular events in an unselected geriatric population: the ICARe Dicomano Study. J Am Coll Cardiol (2008) 2.52

Safety and feasibility of catheter-based local intracoronary vascular endothelial growth factor gene transfer in the prevention of postangioplasty and in-stent restenosis and in the treatment of chronic myocardial ischemia: phase II results of the Kuopio Angiogenesis Trial (KAT). Circulation (2003) 2.48

Cardiovascular events during differing hypertension therapies in patients with diabetes. J Am Coll Cardiol (2010) 2.43

Role of blood pressure and other variables in the differential cardiovascular event rates noted in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA). Lancet (2005) 2.37

Differences in left ventricular structure between black and white hypertensive adults: the Hypertension Genetic Epidemiology Network study. Hypertension (2004) 2.36

Independent association of rheumatoid arthritis with increased left ventricular mass but not with reduced ejection fraction. Arthritis Rheum (2009) 2.33

In-treatment resolution or absence of electrocardiographic left ventricular hypertrophy is associated with decreased incidence of new-onset diabetes mellitus in hypertensive patients: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) Study. Hypertension (2007) 2.27

Genetically determined height and coronary artery disease. N Engl J Med (2015) 2.24

Cardiac remodeling in obesity. Circ Cardiovasc Imaging (2013) 2.24

Baseline heart rate, antihypertensive treatment, and prevention of cardiovascular outcomes in ASCOT (Anglo-Scandinavian Cardiac Outcomes Trial). J Am Coll Cardiol (2009) 2.19

Multifactorial intervention to prevent recurrent cardiovascular events in patients 75 years or older: the Drugs and Evidence-Based Medicine in the Elderly (DEBATE) study: a randomized, controlled trial. Am Heart J (2006) 2.19

Effect of losartan on sudden cardiac death in people with diabetes: data from the LIFE study. Lancet (2003) 2.17